Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
China
· Delayed Price · Currency is CNY 9.41
-0.09 (-0.95%)
Apr 28, 2026, 3:54 PM CST
Xiangxue Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | -1,371 | -858.56 | -388.96 | -530.06 | -688.47 | Upgrade
|
| Depreciation & Amortization | 194.47 | 223.58 | 237.3 | 239.39 | 149.91 | Upgrade
|
| Other Amortization | 6.89 | 19.59 | 8.04 | 7.69 | 14.98 | Upgrade
|
| Loss (Gain) From Sale of Assets | -8.92 | -6.99 | 0.09 | -4.88 | -2.34 | Upgrade
|
| Asset Writedown & Restructuring Costs | 570.32 | 334.92 | 105.38 | 129.73 | 444.56 | Upgrade
|
| Loss (Gain) From Sale of Investments | 0.83 | 4.89 | 60.01 | -47.32 | -49.23 | Upgrade
|
| Other Operating Activities | 316.35 | 275.44 | 270.71 | 249.13 | 269.71 | Upgrade
|
| Change in Accounts Receivable | 40.61 | -54.74 | 62.89 | -106.33 | -14.75 | Upgrade
|
| Change in Inventory | 32.39 | -7.27 | 9.62 | 18.65 | 42.85 | Upgrade
|
| Change in Accounts Payable | 348.69 | 52.61 | -126.51 | 266.28 | 86.44 | Upgrade
|
| Change in Other Net Operating Assets | - | 33.02 | 17.11 | 21.76 | -1.66 | Upgrade
|
| Operating Cash Flow | 139.63 | 18.17 | 263.44 | 227.38 | 257.56 | Upgrade
|
| Operating Cash Flow Growth | 668.28% | -93.10% | 15.86% | -11.72% | 0.15% | Upgrade
|
| Capital Expenditures | -21.51 | -35.24 | -56.03 | -367.27 | -562.74 | Upgrade
|
| Sale of Property, Plant & Equipment | 5.01 | 30.41 | - | 24.71 | 0.17 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -154.32 | Upgrade
|
| Divestitures | - | 41.26 | 0.36 | 435.74 | 59.35 | Upgrade
|
| Investment in Securities | 3.96 | 23.44 | 1.53 | 26.42 | 864.36 | Upgrade
|
| Other Investing Activities | - | -24.91 | 0.48 | 259.67 | -319.63 | Upgrade
|
| Investing Cash Flow | -12.54 | 34.96 | -53.66 | 379.26 | -112.8 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 206.36 | Upgrade
|
| Long-Term Debt Issued | 59.6 | 224.48 | 379.48 | 1,151 | 4,406 | Upgrade
|
| Total Debt Issued | 59.6 | 224.48 | 379.48 | 1,151 | 4,612 | Upgrade
|
| Long-Term Debt Repaid | -65.93 | -206.62 | -429.19 | -1,468 | -4,881 | Upgrade
|
| Total Debt Repaid | -65.93 | -206.62 | -429.19 | -1,468 | -4,881 | Upgrade
|
| Net Debt Issued (Repaid) | -6.33 | 17.86 | -49.71 | -316.96 | -269.06 | Upgrade
|
| Repurchase of Common Stock | - | - | - | -0.27 | -0.38 | Upgrade
|
| Common Dividends Paid | -5.84 | -50.55 | -140.66 | -175.8 | -216.91 | Upgrade
|
| Other Financing Activities | 10.04 | -35.26 | -10.26 | -159.74 | 36.13 | Upgrade
|
| Financing Cash Flow | -2.13 | -67.95 | -200.63 | -652.77 | -450.22 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.02 | 0 | -0 | 0.9 | -0.09 | Upgrade
|
| Net Cash Flow | 124.94 | -14.81 | 9.15 | -45.23 | -305.56 | Upgrade
|
| Free Cash Flow | 118.12 | -17.07 | 207.41 | -139.89 | -305.18 | Upgrade
|
| Free Cash Flow Margin | 7.40% | -0.92% | 9.02% | -6.40% | -10.27% | Upgrade
|
| Free Cash Flow Per Share | 0.18 | -0.03 | 0.32 | -0.21 | -0.46 | Upgrade
|
| Cash Income Tax Paid | 59.18 | 95.72 | 72.13 | 65.98 | 116.17 | Upgrade
|
| Levered Free Cash Flow | 1,668 | 554.16 | 16.29 | 28.83 | 52.33 | Upgrade
|
| Unlevered Free Cash Flow | 1,668 | 699.69 | 164.46 | 162.08 | 178.62 | Upgrade
|
| Change in Working Capital | 430.47 | 25.31 | -29.13 | 183.69 | 118.44 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.